Telix’s TLX66 in Phase II Academic Study of Pediatric Leukemia
Telix announces Phase II academic study of TLX66 in children with high-risk…
Read moreNews & Views
Telix H1 2021 Results and Company Update Conference Call
Telix to hold investor conference call to present H1 2021 financial results and Company…
Read more
Mr. Ryoichi Tanaka Joins Telix Japan as Chief Operating Officer
News,
Telix is delighted to announce that Ryoichi Tanaka has joined the Japan business as Chief Operating Officer and Head of Business…
Read more
First Patient Dosed in CUPID Study of Telix’s Targeted Alpha Therapy Candidate for Prostate Cancer
Telix announces the first patient has been dosed in its ‘CUPID’ Phase I study of TLX592 in patients with advanced prostate…
Read more
Ms. Helen Hovenga Joins Telix as Chief People Officer
News,
Telix is delighted to announce that Ms. Helen Hovenga has joined the Telix executive team in the role of Chief People…
Read more
Telix Seneffe Production Facility: Progress Update
News,
Telix authorised to decommission first of two cyclotrons at Seneffe radiopharmaceutical production…
Read more
Activities Report and Appendix 4C for June 2021 Quarter
Telix provides its Appendix 4C and accompanying Activities Report for the quarter ended 30 June…
Read more
ZIRCON Phase 3 Renal Cancer Imaging Study: Progress Update
Progress update on the ZIRCON Phase 3 study for the imaging of renal cancer with Positron Emission Tomography…
Read more
Telix Appoints Gabrielle Wermenbol as Chief Financial Officer, EMEA
News,
Telix is delighted to announce the appointment of Gabrielle Wermenbol as Chief Financial Officer, Europe, Middle East and Africa…
Read more